Drug Profile
Elezanumab - AbbVie
Alternative Names: ABT-555Latest Information Update: 16 Dec 2022
Price :
$50
*
At a glance
- Originator AbbVie
- Class Monoclonal antibodies; Neuroprotectants; Vascular disorder therapies
- Mechanism of Action RGMA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple sclerosis; Spinal cord injuries; Stroke
Most Recent Events
- 26 Oct 2022 Pooled data from two phase II trials, RADIUS-R and RADIUS-P in Relapsing and Progressive forms of multiple sclerosis were presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2022)
- 28 Sep 2022 Elezanumab is still in phase II trial for Spinal cord injuries in Australia, Canada, Israel, Japan, South Korea, Spain, USA (IV) (NCT04295538)
- 28 Sep 2022 Elezanumab is still in phase II trial for Acute ischaemic stroke in USA, Australia, Canada, Japan, South Korea, Spain (IV) (NCT04309474) (EudraCT2019-003753-29)